Early Real-World Experience with Sibeprenlimab in IgAN (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO0497; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "In 29% (6/21), sibeprenlimab was combined with other immunosuppressive agents, including iptacopan (n=3), steroid taper (n=2), and steroid taper and mycophenolate mofetil (n=1). Adverse events, immunoglobulin levels, eGFR, proteinuria, and hematuria are currently being monitored and will be reported at ASN Kidney Week. Conclusion This study will show the real-world efficacy and safety of sibeprenlimab as a mono- and combination therapy in IgAN, including patients with features that were excluded from clinical trials."
Clinical • Real-world • Real-world evidence • Glomerulonephritis • IgA Nephropathy • Lupus Nephritis • Nephrology • Renal Disease • Vasculitis
|
|
Orhan Efe; Harish Shanthanu Seethapathy; Ashima Chadha; Sydney Aaron; Karen A. Laliberte; John L. Niles; Ayman Al Jurdi
|